Platinum-containing regimens are the mainstay of initial treatment for ovarian cancer and for platinum-sensitive recurrent disease. In recurrent ovarian cancer, the effectiveness of platinum retreatment is dependent on the relapse-free and treatment-free intervals. Platinum agents can be effectively re-administered to patients with disease that relapses >12 months after completion of a platinum regimen. Ovarian cancer that relapses 6-12 months after treatment with a platinum regimen is considered partially platinum sensitive. Phase III studies of combination regimens versus platinum monotherapy and comparing various non-platinum agents administered as monotherapy generally do not report separate data for partially platinum-sensitive patients. Studies reporting data in patients with a platinum-free interval > or =6 months demonstrate advantages for pegylated liposomal doxorubicin (PLD) versus paclitaxel and PLD versus topotecan. A platinum-taxane combination or single-agent PLD is recommended for the treatment of partially platinum-sensitive disease by the UK National Institute for Health and Clinical Excellence.

Colombo, N., & Gore, M. (2007). Treatment of recurrent ovarian cancer relapsing 6-12 months post platinum-based chemotherapy. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 64, 129-138 [10.1016/j.critrevonc.2007.04.004].

Treatment of recurrent ovarian cancer relapsing 6-12 months post platinum-based chemotherapy

COLOMBO, NICOLETTA;
2007-11

Abstract

Platinum-containing regimens are the mainstay of initial treatment for ovarian cancer and for platinum-sensitive recurrent disease. In recurrent ovarian cancer, the effectiveness of platinum retreatment is dependent on the relapse-free and treatment-free intervals. Platinum agents can be effectively re-administered to patients with disease that relapses >12 months after completion of a platinum regimen. Ovarian cancer that relapses 6-12 months after treatment with a platinum regimen is considered partially platinum sensitive. Phase III studies of combination regimens versus platinum monotherapy and comparing various non-platinum agents administered as monotherapy generally do not report separate data for partially platinum-sensitive patients. Studies reporting data in patients with a platinum-free interval > or =6 months demonstrate advantages for pegylated liposomal doxorubicin (PLD) versus paclitaxel and PLD versus topotecan. A platinum-taxane combination or single-agent PLD is recommended for the treatment of partially platinum-sensitive disease by the UK National Institute for Health and Clinical Excellence.
Articolo in rivista - Articolo scientifico
Recurrent ovarian cancer; Pegylated liposomal doxorubicin; Paclitaxel; Platinum; Topotecan
English
Colombo, N., & Gore, M. (2007). Treatment of recurrent ovarian cancer relapsing 6-12 months post platinum-based chemotherapy. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 64, 129-138 [10.1016/j.critrevonc.2007.04.004].
Colombo, N; Gore, M
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10281/14422
Citazioni
  • Scopus 73
  • ???jsp.display-item.citation.isi??? 71
Social impact